搜尋
Yahoo! 財經
你好!Guest
[ 用戶登入新用戶? ]

IR Biosciences Holdings Inc.
(IRBS.OB)

0.00 (0.00%)
0.350
最新價
2010年2月10日 上午 4:39 HKT
買入: N/A昨日收市: N/A
賣出: N/A開市: N/A
今日波幅: N/A

基本資料

其他股份的基本資料:
IR Biosciences Holdings Inc.
8777 East Via de Ventura
Suite 280
Scottsdale, AZ 85258
Phone: 480-922-3926
Fax: 480-922-4781
Web Site: http://www.immuneregen.com

 DETAILS 
Index Membership:N/A
Sector:Services
Industry:Research Services
Employees (last reported count):10

 REUTERS ABRIDGED BUSINESS SUMMARY 
IR BioSciences Holdings, Inc., a development-stage biotechnology company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of Homspera and its derivatives, Radilex and Viprovex. The company’s product lines are designed to be used as countermeasures for homeland security threats, including radiological, chemical, and biological agents. Its Homspera is an analog of the endogenous neurokinin Substance P that is in advanced preclinical stages for immune/stem cell stimulation and wound healing. The company’s Radilex is in preclinical stagesof development for use as a potential treatment for acute exposure to radiation; and Viprovex is in preclinical stages of development for the treatment of exposure to biological agents, such as infectious disease, which include influenza and anthrax. The company was founded in 1999 and is headquartered in Scottsdale, Arizona.
Key Statistics
More from Reuters
Expanded Business Description

 COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on IR Biosciences Holdings Inc.


    More from Reuters
    Reuters offers more in-depth Company Research , Stock Screening , and >Risk Alerts on over 10,000 U.S. Equities.

     REUTERS ABRIDGED FINANCIAL SUMMARY 
    View Financials
    More from Reuters
    Significant Developments - Highlights - Performance - Ratio Comparison


     OFFICERS 
     PayExercised
    Mr. Michael K. Wilhelm , 42
    Co-Founder, Chairman, Chief Exec. Officer, Pres, Member of Exec. Committee, Co-Founder of ImmuneRegen BioSciences Inc, Chief Exec. Officer of ImmuneRegen BioSciences Inc, Pres of ImmuneRegen BioSciences Inc of ImmuneRegen BioSciences Inc
    N/A N/A
    Mr. John N. Fermanis , 56
    Chief Financial Officer and Principal Accounting Officer
    $ 137.00KN/A
    Dr. Hal N. Siegel Ph.D., 55
    Chief Scientific Officer, VP, Director and Member of Scientific Advisory Board
    N/A N/A
    Ms. Michelle R. Laroche ,
    Sec. and Sec. of Immuneregen Biosciences Inc
    N/A N/A
    Dr. K. A. Kelly McQueen MD, MPH, PLLC,
    Consultant, Member of Scientific Advisory Board and Member of Bioterrorism Preparedness Advisory Board
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders
    More from Reuters:
    Full List - Bios - Compensation - Options


    加進我的投資組合 加進我的投資組合    寄給朋友 寄給朋友

    資料提供及版權歸於 AASTOCKSDBPower經濟通內幕人 Insiders.hkInteractive Data Real Time Services凱基証券QuamnetTelekurs (USA) INC
    用戶意見 | 私隱政策 | 服務條款 | 免責條款
    Copyright © 2010 Yahoo! Hong Kong Limited. All rights reserved. 版權所有 不得轉載
    免責聲明:以上資料由雅虎香港有限公司的資料提供夥伴(如AASTOCKS、DBPower、經濟通、內幕人Insiders.hk、Interactive Data Real Time Services、凱基証券、Quamnet 和 Telekurs (USA) INC)提供,僅作參考之用,雅虎香港有限公司及資料提供夥伴對以上資訊的準性和可靠性不能亦不會作任何保證或承擔,並對基於該等資料或有關的錯漏或延誤而作出的任何決定或導致的損失概不負責。
    權益披露包括: 法團大股東之交易, 個人大股東之交易, 董事或最高行政人員之交易,及董事或最高行政人員買賣其上市公司的子公司或付屬公司之交易。
    所有股票報價及認股證報價均延遲最少十五分鐘。